In patients with stage IIIA non–small-cell lung cancer (NSCLC), should the presence of N2 disease be determined by both radiologic and invasive staging prior to treatment initiation? Are ALK rearrangements and EGFR mutations mutually exclusive? Test your knowledge in our latest quiz.
A 54-year-old woman, who is a never-smoker, presents with swollen lymph nodes, cough, and dyspnea. Initial abnormal chest x-ray followed by CT reveals a right upper-lobe lung mass, and bilateral supraclavicular and mediastinal lymph nodes. Biopsy results of the lung mass show adenocarcinoma. Molecular testing reveals an EGFR exon 19 deletion.